Q4 2023 · 13F-HR
Deep Track Capital, LPholdings as filed
Filed 2024-02-14 · accession 0001856083-24-000001
$2.99B
Reported value
60
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 457669307 | INSM | INSMED INC | $165.8M | 5.54% | 5,350,000 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $148.3M | 4.95% | 4,063,676 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $143.2M | 4.78% | 2,000,000 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $135.3M | 4.52% | 5,000,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $114.1M | 3.81% | 300,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $112.5M | 3.76% | 1,347,300 | CALL | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $111.0M | 3.71% | 4,000,000 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $104.1M | 3.48% | 5,750,000 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $99.2M | 3.31% | 7,093,214 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $79.6M | 2.66% | 1,000,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $79.1M | 2.64% | 3,631,728 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $76.4M | 2.55% | 11,869,297 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $68.7M | 2.29% | 7,000,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $68.6M | 2.29% | 2,250,000 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $66.3M | 2.21% | 7,370,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $64.9M | 2.17% | 2,323,456 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $63.4M | 2.12% | 3,187,415 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $63.2M | 2.11% | 1,249,068 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $63.1M | 2.11% | 3,490,506 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $62.4M | 2.08% | 29,583,449 | Common | SOLE |
| 28106W103 | EDIT | EDITAS MEDICINE INC | $55.4M | 1.85% | 5,473,086 | Common | SOLE |
| 641871108 | — | AMBRX BIOPHARMA INC | $52.8M | 1.76% | 3,710,412 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $48.2M | 1.61% | 500,000 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $47.5M | 1.59% | 1,815,854 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $46.5M | 1.55% | 2,900,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $46.3M | 1.55% | 2,284,372 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $46.0M | 1.54% | 4,297,438 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $44.6M | 1.49% | 1,793,966 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $43.6M | 1.46% | 2,036,990 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $42.1M | 1.41% | 1,000,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $42.0M | 1.40% | 1,952,760 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $41.2M | 1.37% | 9,230,769 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $40.2M | 1.34% | 725,145 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $39.6M | 1.32% | 6,100,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $33.9M | 1.13% | 1,951,580 | Common | SOLE |
| 68570P200 | — | ORCHARD THERAPEUTICS PLC | $33.6M | 1.12% | 2,041,670 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $33.1M | 1.11% | 450,000 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $33.1M | 1.10% | 600,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $30.9M | 1.03% | 2,997,830 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $27.8M | 0.93% | 2,537,176 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $27.1M | 0.90% | 1,930,894 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $26.6M | 0.89% | 2,000,000 | Common | SOLE |
| 00847G705 | AGENEUR | AGENUS INC | $26.2M | 0.88% | 31,697,539 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $24.1M | 0.81% | 288,949 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $23.7M | 0.79% | 1,062,881 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $21.8M | 0.73% | 2,992,731 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $19.0M | 0.64% | 1,011,829 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $18.2M | 0.61% | 500,000 | CALL | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $12.2M | 0.41% | 300,000 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $11.8M | 0.39% | 2,523,000 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $10.4M | 0.35% | 18,400,000 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $9.1M | 0.30% | 250,000 | PUT | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $8.5M | 0.28% | 2,044,507 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $6.9M | 0.23% | 2,510,736 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $6.5M | 0.22% | 828,485 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $6.3M | 0.21% | 275,201 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $5.9M | 0.20% | 48,280 | Common | SOLE |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $5.4M | 0.18% | 1,594,931 | Common | SOLE |
| 01626L105 | — | ALIGOS THERAPEUTICS INC | $4.1M | 0.14% | 6,102,770 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $2.9M | 0.10% | 499,400 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.